Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.78 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.78 |
| ▸ | CHRNA7 | P36544 | 14/20 | 0.77 |
| ▸ | HTR3A | P46098 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372874 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372931 | 0.86 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL373249 | 0.86 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL373382 | 0.86 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL373068 | 0.85 | CHRNA7 (0.74) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL15882741 | 0.85 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372320 | 0.85 | CHRNA7 (0.76) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL372978 | 0.84 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA7KCNH2 | |
| SCHEMBL372998 | 0.84 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL373537 | 0.84 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2633868-A1 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| US-20110059947-A1 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | TARGACEPT, INC. (US) | 2011-03-10 | — | — | US | claimed |
| EP-2254598-A2 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept Inc. (US) | 2010-12-01 | — | — | EP | claimed |
| WO-2009102962-A2 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | TARGACEPT, INC. (US) | 2009-08-20 | — | — | WO | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2633868-A1 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110059947-A1 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | TARGACEPT, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2254598-A2 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2185152-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Targacept Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009102962-A2 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | TARGACEPT, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009018511-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059947-A1 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | CHRNA7, CHRNA5, CHRNA4 | CHRNB2 14/4885CHRNA4 3/4885CHRNA7 1/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNB2 6/4885CHRNA4 3/4885CHRNA7 1/4885 |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | CHRNA7, CHRNA1, CHRNG | CHRNB2 17/4885CHRNA4 9/4885CHRNA7 1/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | CHRNB2 6/4885CHRNA4 2/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.